WebUS5635388A * 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof. DE19727814C1 * 1997-06-30 1998-10-01 Univ Eberhard Karls Monoclonal antibody specific for human tyrosine kinase receptor protein. WO2024222935A1 * 2024-06-02 2024-12-06 Pfizer Inc. Chimeric antigen receptors … WebMar 27, 2024 · agonist antibodies flt3 flt3 agonist agonistic antibodies antibodies Prior art date 2024-12-18 Application number CR20240327A Other languages Spanish (es) Inventor Melissa Beilschmidt Dorothea Maetzel Johan Fransson Phil Gobeil Arif Jetha Original Assignee Boehringer Ingelheim Io Canada Inc
History of Changes for Study: NCT05029999 - clinicaltrials.gov
WebJun 15, 2024 · Abstract. Introduction: Triple negative breast cancers (TNBC) have shown limited responses to immune checkpoint blockade (ICB). Breast cancer is associated with defects in antigen presentation which may contribute to resistance to ICB. Flt3 ligand (Flt3L) is a growth factor that increases differentiation of DC1 dendritic cells, critical mediators of … WebFLT3 pathway stimulation using GS-3583, a novel FLT3 agonistic Fc fusion protein, has the potential to promote T cell mediated anti-tumor activity. We sought to evaluate the … is cloud fog
ECSP21044672A - FLT3 AGONIST ANTIBODIES AND THEIR USES
WebSep 13, 2024 · Several OX2R agonists have been reported but with little or no activity at OX1R. We conducted structure–activity relationship studies … WebAgonist antibodies against the flk2/flt3 receptor and uses thereof PCT/US1995/003718 WO1995027062A1 (en) 1994-04-04: 1995-03-23: Agonist antibodies against the flk2/flt3 receptor and uses thereof Publications (2) Publication Number Publication Date; DE69509647D1 DE69509647D1 ... WebFLT3 is a key factor for the differentiation and maturation of cDCs; thus, FLT3 agonist, CDX-301 (FLT3L), has been developed (Kvedaraite and Ginhoux, 2024). rv co-op parks